Regeneron's Eylea still racing ahead; Strong Opsumit launch boosts Actelion forecast; Diabetes texts kept patients on meds;

> Regeneron's ($REGN) Eylea drug continues to grow by leaps and bounds, with $610 million in fourth quarter sales, up from $415 million a year ago. Report

> The Swiss drugmaker Actelion hiked its 2014 earnings forecast after its new treatment for pulmonary arterial hypertension, Opsumit, got off to a better-than-expected start. Report

> A 6 month experiment in diabetes management, using mobile communications including texts, boosted prescription costs because of better drug adherence, but saved more than $32,000 on doctor visits, ER trips and other services. Report

> Seattle Genetics ($SGEN) promoted two commercial executives--Chris Boerner, to EVP, Commercial; and Charles (Chip) Romp to SVP, Sales--and added David Fontana as VP of portfolio management and Adcetris program manager. Release

> Keryx Biopharmaceuticals brought on Greg Madison as EVP and chief operating officer; he will be charged with building a commercial organization to support the potential launch of Zerenex, a drug for kidney patients. Release

And Finally... Some doctors argue caution in using new obesity drugs from Arena Pharmaceuticals ($ARNA) and Vivus ($VVUS). Report

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.

Merck’s Keytruda went up against chemo in a head-to-head colorectal cancer battle—and won.